Cover Image
市場調查報告書

癌症診斷的全球市場預測 2020年:ELISA, ELFA, PCR (聚合酵素鏈鎖反應) , NGS (次世代定序) , IHC (免疫組織化學)

Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020

出版商 MarketsandMarkets 商品編碼 332701
出版日期 內容資訊 英文 181 Pages
訂單完成後即時交付
價格
Back to Top
癌症診斷的全球市場預測 2020年:ELISA, ELFA, PCR (聚合酵素鏈鎖反應) , NGS (次世代定序) , IHC (免疫組織化學) Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020
出版日期: 2015年06月10日 內容資訊: 英文 181 Pages
簡介

全球癌症診斷市場依技術、用途及地區分類。技術進一步分為平台型和設備型。在2015年中,設備型區分構成該市場很大的佔有率。生物標記,成像,切片檢查,內視鏡等各種領域的技術進步,癌症病例數的增加,老年人口的劇增,政府措施的認識,及政府資金的增加,成為促進全球癌症診斷市場成長的主要原因。可是,生物標記的高額資本投資和低收益成本比率,及熟練專家的不足,抑制該市場的成長。新興各國的醫療基礎設施的改善及搭配診斷的需求擴大,提供成長機會給癌症診斷市場。

本報告提供全球癌症診斷市場相關調查、市場概要、各產品、用途、地區的市場規模與預測、競爭環境分析,及主要企業簡介等資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 全球癌症診斷市場
  • 癌症診斷市場的各地區概述
  • 癌症診斷市場:各技術

第5章 市場概要

  • 主要調查結果
  • 簡介
  • 市場動態

第6章 全球癌症診斷市場:各技術

  • 簡介
  • 平台為基礎的癌症診斷
    • 聚合酵素鏈鎖反應 (PCR)
    • in Situ 雜合反應 (ISH)
    • 免疫組織化學 (IHC)
    • 次世代定序 (NGS)
    • 微陣列
    • 流式細胞技術
    • 其他技術
  • 設備為基礎的癌症診斷
    • 影像診斷
    • 活體組織切片 (切片檢查)

第7章 全球癌症診斷市場:各用途

  • 簡介
    • 乳癌
    • 肺癌
    • 大腸癌
    • 黑色素瘤
    • 其他癌症

第8章 市場:各終端用戶

第9章 全球癌症診斷市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區 (RoW)

第10章 競爭情形

  • 概要
  • 市場佔有率分析
  • 競爭情形、趨勢

第11章 企業簡介

  • 簡介
  • Becton, Dickinson and Company
  • GE Healthcare (General Electric Company 的子公司)
  • Abbott
  • Roche
  • Thermo Fisher Scientific, Inc.
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • Siemens Healthcare
  • C.R. Bard, Inc.

第12章 附錄

圖表一覽

目錄
Product Code: MD 3480

According to the CDC, cancer is the second leading cause of mortality, causing ~584,881 deaths worldwide in 2013. Early diagnosis is the key to prevent the rising number of cancer-related deaths. The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms such as next-generation sequencing, DNA microarrays, and polymerase chain reaction (PCR). Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market.

The instrument-based cancer diagnostics segment accounted for the largest share of the global the cancer diagnostics market, by technology, while breast cancer accounted for the largest share of the cancer diagnostics applications market, in 2014.

North America accounted for the largest share of the global cancer diagnostics market, followed by Europe, Asia, and the Rest of the World (RoW). In the coming years, the cancer diagnostics market is expected to experience the highest growth rate in the Asian region, with emphasis on India and China. These countries are expected to serve as revenue pockets for companies operating in the cancer diagnostics market.

The global cancer diagnostics market witnesses high competitive intensity as there are several big and many small firms operating in different segments of the market. These companies adopt various strategies (agreements/partnerships/joint ventures/collaborations, new product launches, geographical expansions, and acquisitions) to increase their market shares and establish a strong foothold in the global market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the cancer diagnostics market. The report analyzes cancer diagnostics by technology, application, and geography
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the cancer diagnostics market
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various cancer diagnostic technologies across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the cancer diagnostics market
  • Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the cancer diagnostics market

Table of Contents

1. Introduction

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Scope
    • 1.3.1. Markets Covered
    • 1.3.2. Years Considered for the Study
  • 1.4. Currency
  • 1.5. Limitations
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1.1. Research Methodology Steps
  • 2.1.2. Secondary and Primary Research Methodology
    • 2.1.2.1. Secondary Research
    • 2.1.2.2. Key Data From Secondary Sources
    • 2.1.2.3. Primary Research
    • 2.1.2.4. Key Industry Insights
  • 2.1.5. Key Data From Primary Sources
  • 2.1.6. Key Insights From Primary Sources
  • 2.1.7. Market Size Estimation Methodology
  • 2.1.8. Market Forecast Methodology
  • 2.1.9. Market Data Validation and Triangulation
  • 2.1.10. Assumptions for the Study

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Current Scenario
  • 3.3. Future Outlook
  • 3.4. Conclusion

4. Premium Insights

  • 4.1. Global Cancer Diagnostics Market
  • 4.2. Regional Snapshot of the Cancer Diagnostics Market
  • 4.3. Cancer Diagnostics Market, By Technology (2015 vs. 2020)

5. Market Overview

  • 5.1. Key Findings
  • 5.2. Introduction
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
      • 5.3.1.1. Rising Prevalence of Cancer
      • 5.3.1.2. Technological Advancements
      • 5.3.1.3. Initiatives Undertaken By Governments and Global Health Organizations to Spread Awareness About Cancer
      • 5.3.1.4. Growth in the Number of Private Diagnostic Centers
      • 5.3.1.5. Public-Private Partnerships to Enhance the Infrastructure of Diagnostic Imaging Centers
      • 5.3.1.6. Fda Support for Biomarker Development
      • 5.3.1.7. Launch of New Flow Cytometry Reagents for Diagnostics and Drug Discovery
    • 5.3.2. Restraints
      • 5.3.2.1. High Capital Investments & Low Benefit-Cost Ratio for Biomarkers
      • 5.3.2.2. Shortage of Helium
      • 5.3.2.3. High Cost of Diagnostic Imaging Systems Affecting Their Rate of Adoption in Emerging Markets
      • 5.3.2.4. Risk of High Radiation Exposure Likely to Limit the Usage of CT Scanners
      • 5.3.2.5. Dearth of Skilled and Experienced Personnel
    • 5.3.3. Opportunities
      • 5.3.3.1. Personalized Medicine
      • 5.3.3.2. Development of Mass Cytometry and the Combination of Cell-And Bead-Based Flow Cytometry Technologies
      • 5.3.3.3. Companion Diagnostics
      • 5.3.3.4. Improving Healthcare Infrastructure in Emerging Markets
      • 5.3.3.5. Miniaturized and Technologically Advanced Devices
    • 5.3.4. Challenges
      • 5.3.4.1. Stringent Regulatory Guidelines
      • 5.3.4.2. Hospital Budget Cuts A Key Challenge to Market Players
      • 5.3.4.3. Increasing Adoption of Refurbished Diagnostic Imaging Systems

6. Global Cancer Diagnostics Market, By Technology

  • 6.1. Introduction
  • 6.2. Platform-Based Diagnostics
    • 6.2.1. Polymerase Chain Reaction (PCR)
    • 6.2.2. in Situ Hybridization (ISH)
    • 6.2.3. Immunohistochemistry (IHC)
    • 6.2.4. Next-Generation Sequencing (NGS)
    • 6.2.5. Microarrays
    • 6.2.6. Flow Cytometry
    • 6.2.7. Other Technologies
  • 6.3. Instrument-Based
    • 6.3.1. Diagnostic Imaging
      • 6.3.1.1. Magnetic Resonance Imaging (MRI)
      • 6.3.1.2. Computed Tomography (Ct)
      • 6.3.1.3. Positron Emission Tomography (PET)
        • 6.3.1.3.1. Standalone Positron Emission Tomography
        • 6.3.1.3.2. Hybrid Positron Emission Tomography
      • 6.3.1.4. Mammography
      • 6.3.1.5. Ultrasound
    • 6.3.2. Biopsies

7. Global Cancer Diagnostics Market, By Application

  • 7.1. Introduction
    • 7.1.1. Breast Cancer
    • 7.1.2. Lung Cancer
    • 7.1.3. Colorectal Cancer
    • 7.1.4. Melanoma
    • 7.1.5. Other Cancers

8. Market, By End User

9. Cancer Diagnostics Market, By Region

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. U.S.
      • 9.2.1.1. Government Initiatives
      • 9.2.1.2. Increase in Cancer Incidence
    • 9.2.2. Canada
      • 9.2.2.1. High Incidence of Cancer
      • 9.2.2.2. Government Funding
  • 9.3. Europe
    • 9.3.1. Funding for Cancer Diagnostics Research
    • 9.3.2. Eu-5. (U.K., Germany, France, Italy, Spain)
      • 9.3.2.1. Strong Government Support
      • 9.3.2.2. Research Collaborations
      • 9.3.2.3. Increase in Diagnostic Imaging Centers
      • 9.3.2.4. Rising Public and Private Investments
    • 9.3.3. Rest of Europe (RoE)
      • 9.3.3.1. Aging Population
      • 9.3.3.2. Conferences Boosting Awareness
      • 9.3.3.3. Government Investments in Russia
  • 9.4. Asia
    • 9.4.1.1. China
      • 9.4.1.1.1. Expansion of International Players
      • 9.4.1.1.2. Aging Population and Increasing Cancer Incidence
    • 9.4.1.2. Japan
      • 9.4.1.2.1. Aging Population and High Healthcare Expenditure in Japan
    • 9.4.1.3. India
      • 9.4.1.3.1. Increasing Focus of International Players on India
    • 9.4.1.4. Rest of Asia
      • 9.4.1.4.1. Presence of International Players Boosting Market Growth
  • 9.5. Rest of the World (RoW)
    • 9.5.1.1. Government Initiatives Boosting Demand for Cancer Diagnostics
    • 9.5.1.2. Aging Population, Presence of International Players
    • 9.5.1.3. Increase in Cancer Incidences and Rising Government Expenditure
    • 9.5.1.4. Government Initiatives to Improve Healthcare Infrastructure

10. Competitive Landscape

  • 10.1. Overview
  • 10.2. Market Share Analysis
  • 10.3. Competitive Situation and Trends
    • 10.3.1. Collaborations/Agreements/Partnerships/Alliances
    • 10.3.2. New Product Launches
    • 10.3.3. Acquisitions
    • 10.3.4. Expansion
    • 10.3.5. Others

11. Company Profiles

  • 11.1. Introduction
  • 11.3. Becton, Dickinson and Company
    • 11.3.1. Business Overview
    • 11.3.2. Product Portfolio
    • 11.3.3. Key Strategy
    • 11.3.4. Recent Developments
  • 11.4. GE Healthcare (A Subsidiary of General Electric Company)
    • 11.4.1. Business Overview
    • 11.4.2. Product Portfolio
    • 11.4.3. Key Strategy
    • 11.4.4. Recent Developments
  • 11.5. Abbott
    • 11.5.1. Business Overview
    • 11.5.2. Product Portfolio
    • 11.5.3. Key Strategy
    • 11.5.4. Recent Developments
  • 11.6. Roche
    • 11.6.1. Business Overview
    • 11.6.2. Product Portfolio
    • 11.6.3. Key Strategy
    • 11.6.4. Recent Developments
  • 11.7. Thermo Fisher Scientific, Inc.
    • 11.7.1. Business Overview
    • 11.7.2. Thermo Fisher Scientific, Inc.: Company Snapshot
    • 11.7.3. Product Portfolio
    • 11.7.4. Key Strategy
    • 11.7.5. Recent Developments
  • 11.8. Agilent Technologies, Inc.
    • 11.8.1. Business Overview
    • 11.8.2. Agilent Technologies, Inc.: Company Snapshot
    • 11.8.3. Product Portfolio
    • 11.8.4. Key Strategy
    • 11.8.5. Recent Developments
  • 11.9. Illumina, Inc.
    • 11.9.1. Business Overview
    • 11.9.2. Product Portfolio
    • 11.9.3. Key Strategy
    • 11.9.4. Recent Developments
  • 11.10. Siemens Healthcare
    • 11.10.1. Business Overview
    • 11.10.2. Product Portfolio
    • 11.10.3. Key Strategy
    • 11.10.4. Recent Developments
  • 11.11. C.R. Bard, Inc.
    • 11.11.1. Business Overview
    • 11.11.2. Product Portfolio
    • 11.11.3. Key Strategy
    • 11.11.4. Recent Developments

12. Appendix

  • 12.1. Discussion Guide
  • 12.2. Available Customizations
  • 12.3. Related Reports
  • 12.4. Introducing RT: Real-Time Market Intelligence

List of Tables

  • Table 1: Rising Prevalence of Cancer is Driving the Growth of the Cancer Diagnostics Market
  • Table 2: High Capital Investment Restraining the Growth of this Market
  • Table 3: Emerging Markets Present an Array of Opportunities for the Growth of this Market
  • Table 4: Stringent Regulatory Guidelines are A Major Challenge in the Cancer Diagnostics Market
  • Table 5: Global Cancer Diagnostics Market Size, By Technology, 2013-2020 ($Million)
  • Table 6: Global Market Size, By Technology, 2013-2020 ($Million)
  • Table 7: Market Size for Platform-Based Diagnostics, By Region, 2013-2020 ($Million)
  • Table 8: Global Market Size for PCR, By Region, 2013-2020 ($Million)
  • Table 9: Global Market Size for PCR, By Application, 2013-2020 ($Million)
  • Table 10: Cancer Diagnostics Market Size for in Situ Hybridization, By Region, 2013-2020 ($Million)
  • Table 11: Global Market Size for in Situ Hybridization, By Application, 2013-2020 ($Million)
  • Table 12: Market Size for Immunohistochemistry, By Region, 2013-2020 ($Million)
  • Table 13: Global Market Size for Immunohistochemistry, By Application, 2013-2020 ($Million)
  • Table 14: Market Size for NGS, By Region, 2013-2020 ($Million)
  • Table 15: Global Market Size for NGS, By Application, 2013-2020 ($Million)
  • Table 16: Market Size for Microarrays, By Region, 2013-2020 ($Million)
  • Table 17: Global Market Size for Microarrays, By Application, 2013-2020 ($Million)
  • Table 18: Market Size for Flow Cytometry, By Region, 2013-2020 ($Million)
  • Table 19: Global Market Size for Flow Cytometry, By Application, 2013-2020 ($Million)
  • Table 20: Market Size for Other Technologies, By Region, 2013-2020 ($Million)
  • Table 21: Global Market Size for Other Technologies, By Application, 2013-2020 ($Million)
  • Table 22: Global Market Size, By Technology, 2013-2020 ($Million)
  • Table 23: Cancer Diagnostics Market Size for Diagnostic Imaging, By Product, 2013-2020 ($Million)
  • Table 24: Market Size for Diagnostic Imaging, By Region, 2013-2020 ($Million)
  • Table 25: Global Market Size for Imaging, By Application, 2013-2020 ($Million)
  • Table 26: Cancer Diagnostics Market Size for MRI, By Region, 2013-2020 ($Million)
  • Table 27: Market Size for CT, By Region, 2013-2020 ($Million)
  • Table 28: Market Size for PET, By Product, 2013-2020 ($Million)
  • Table 29: Market Size for PET, By Region, 2013-2020 ($Million)
  • Table 30: Market Size for Standalone PET, By Region, 2013-2020 ($Million)
  • Table 31: Market Size for Hybrid PET, By Region, 2013-2020 ($Million)
  • Table 32: Market Size for Mammography, By Region, 2013-2020 ($Million)
  • Table 33: Market Size for Ultrasound, By Region, 2013-2020 ($Million)
  • Table 34: Cancer Diagnostics Market Size for Biopsy, By Region, 2013-2020 ($Million)
  • Table 35: Global Market Size for Biopsy, By Application, 2013-2020 ($Million)
  • Table 36: Global Market Size, By Application, 2013-2020 ($Million)
  • Table 37: Market Size for Breast Cancer, By Region, 2013-2020 ($Million)
  • Table 38: Market Size for Lung Cancer, By Region, 2013-2020 ($Million)
  • Table 39: Market Size for Colorectal Cancer, By Region, 2013-2020 ($Million)
  • Table 40: Market Size for Melanoma, By Region, 2013-2020 ($Million)
  • Table 41: Cancer Diagnostics Market Size for Other Cancers, By Region, 2013-2020 ($Million)
  • Table 42: North America Market, By Country, 2013-2020 ($Million)
  • Table 43: North America: Market, By Technology, 2013-2020 ($Million)
  • Table 44: North America: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 45: North America: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 46: North America: Market, By Application, 2013-2020 ($Million)
  • Table 47: U.S.: Market, By Technology, 2013-2020 ($Million)
  • Table 48: U.S.: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 49: U.S.: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 50: Canada: Market, By Technology, 2013-2020 ($Million)
  • Table 51: Canada: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 52: Canada: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 53: Europe: Market, By Region, 2013-2020 ($Million)
  • Table 54: Europe: Market, By Technology, 2013-2020 ($Million)
  • Table 55: Europe: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 56: Europe: Cancer Diagnostics Instrument Market, By Technology, 2013-2020 ($Million)
  • Table 57: Europe: Market, By Application, 2013-2020 ($Million)
  • Table 58: EU-5: Market, By Technology, 2013-2020 ($Million)
  • Table 59: EU-5: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 60: EU-5: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 61: RoE: Market, By Technology, 2013-2020 ($Million)
  • Table 62: RoE: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 63: RoE: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 64: Asia: Market, By Country, 2013-2020 ($Million)
  • Table 65: Asia: Market, By Technology, 2013-2020 ($Million)
  • Table 66: Asia: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 67: Asia: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 68: Asia: Market, By Application, 2013-2020 ($Million)
  • Table 69: China: Market, By Technology, 2013-2020 ($Million)
  • Table 70: China: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 71: China: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 72: Japan: Market, By Technology, 2013-2020 ($Million)
  • Table 73: Japan: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 74: Japan: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 75: India: Market, By Technology, 2013-2020 ($Million)
  • Table 76: India: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 77: India: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 78: RoA: Market, By Technology, 2013-2020 ($Million)
  • Table 79: RoA: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 80: RoA: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 81: RoW: Market, By Technology, 2013-2020 ($Million)
  • Table 82: RoW: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 83: RoW: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 84: RoW: Market, By Application, 2013-2020 ($Million)
  • Table 85: Collaborations/Agreements/Partnerships/Alliances, 2012-2015
  • Table 86: New Product Launches, 2012-2015
  • Table 87: Acquisitions, 2012-2015
  • Table 88: Expansions, 2012-2015
  • Table 89: Other Strategies, 2012-2015

List of Figures

  • Figure 1: Cancer Diagnostics Market Segmentation
  • Figure 2: Global Cancer Diagnostics Market : Research Methodology Steps
  • Figure 3: Sampling Frame: Primary Research
  • Figure 4: Break Down of Primary Interviews: By Company Type, Designation, and Region
  • Figure 5: Market Size Estimation Methodology: Bottom-Up Approach
  • Figure 6: Market Size Estimation Methodology: Top-Down Approach
  • Figure 7: Market Forecast Methodology
  • Figure 8: Data Triangulation Methodology
  • Figure 9: Platform-Based Diagnostics to Witness Highest CAGR of 25.3% From 2015 to 2020
  • Figure 10: Global Platform-Based Cancer Diagnostics Market Share, By Technology, 2015-2020
  • Figure 11: Global Cancer Diagnostics Market, By Geography
  • Figure 12: Largest and Fastest-Growing Cancer Diagnostic Applications, 2015-2020
  • Figure 13: Cancer Diagnostics Market Likely to Grow at A CAGR of 12.9% in the Forecast Period
  • Figure 14: Market, By Region and Application: North America Will Dominate the Cancer Diagnostics Market in 2015
  • Figure 15: Asia to Witness the Highest Growth Rate During the Forecast Period
  • Figure 16: Instrument-Based Technology Will Command Largest Market Share
  • Figure 17: Market: Drivers, Restraints, Opportunities, & Challenges
  • Figure 18: NGS, A Ground-Breaking Technology in Cancer Diagnosis
  • Figure 19: Ultrasound Accounted for the Largest Share of the Cancer Diagnostics Market for Imaging
  • Figure 20: Market Growth Will Be Driven By Rising Incidence & Prevalence of Breast and Lung Cancers
  • Figure 21: Lung Cancer Application is Expected to Grow at the Highest CAGR in the Forecast Period
  • Figure 22: New Product Launches Was the Key Growth Strategy for Market Players
  • Figure 23: Global NGS Market (For Cancer Diagnostics) Share Analysis, By Key Player, 2014
  • Figure 24: Global Microarrays Market (For Cancer Diagnostics) Share Analysis, By Key Player, 2014
  • Figure 25: Global Flow Cytometry (For Cancer Diagnostics) Market Share Analysis, By Key Player, 2014
  • Figure 26: Global MRI Imaging Market Share Analysis, By Key Player, 2014
  • Figure 27: Global CT Imaging Market Share Analysis, By Key Player, 2014
  • Figure 28: Global PET Imaging Market Share Analysis, By Key Player, 2014
  • Figure 29: Global Ultrasound Imaging Market Share Analysis, By Key Player, 2014
  • Figure 30: Battle for Market Share: Collaborations/Agreements/Partnerships/ Alliances Were Key Strategies
  • Figure 31: Becton, Dickinson and Company: Company Snapshot
  • Figure 32: GE Healthcare: Company Snapshot
  • Figure 33: Abbott: Company Snapshot
  • Figure 34: Roche Diagnostics: Company Snapshot
  • Figure 35: Illumina, Inc.: Company Snapshot
  • Figure 36: Siemens: Company Snapshot
  • Figure 37: C.R. Bard, Inc.: Company Snapshot
Back to Top